Sumi Lee, Jae Woong Koh, Jung-Hee Lee, Seon-Joo Park
{"title":"Silencing of Acyl-CoA Thioesterase 7 Inhibits Proliferation and Metastatic Potential in Colorectal Cancer Cells.","authors":"Sumi Lee, Jae Woong Koh, Jung-Hee Lee, Seon-Joo Park","doi":"10.21873/anticanres.17692","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Acyl-CoA thioesterase 7 (<i>ACOT7</i>) has emerged as a candidate gene implicated in various malignancies. However, its functional relevance in colorectal cancer (CRC) remains poorly understood.</p><p><strong>Materials and methods: </strong>To investigate the role of ACOT7 in CRC, we examined its expression in normal colon epithelial cells and a panel of CRC cell lines using quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting. Functional analyses were performed following siRNA-mediated knockdown of <i>ACOT7</i> to assess changes in cell proliferation, clonogenicity, cell cycle distribution, apoptosis, migration, and invasion using MTT, colony formation, flow cytometry, and Transwell-based assays.</p><p><strong>Results: </strong>ACOT7 was markedly over-expressed at both the mRNA and protein levels in CRC cells compared to normal epithelial cells. Silencing <i>ACOT7</i> substantially reduced cell proliferation and clonogenic potential. Flow cytometric analysis indicated cell cycle arrest and an increase in the sub-G<sub>0</sub>/G<sub>1</sub> population, indicative of apoptosis in ACOT7-depleted cells. Furthermore, suppression of <i>ACOT7</i> substantially impaired both cell migration and invasion, suggesting its key role in metastatic progression.</p><p><strong>Conclusion: </strong>These findings highlight <i>ACOT7</i> as a critical regulator of the proliferation, survival, and metastatic potential of CRC cells and support its candidacy as a potential therapeutic target for colorectal malignancies.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3315-3325"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17692","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Acyl-CoA thioesterase 7 (ACOT7) has emerged as a candidate gene implicated in various malignancies. However, its functional relevance in colorectal cancer (CRC) remains poorly understood.
Materials and methods: To investigate the role of ACOT7 in CRC, we examined its expression in normal colon epithelial cells and a panel of CRC cell lines using quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting. Functional analyses were performed following siRNA-mediated knockdown of ACOT7 to assess changes in cell proliferation, clonogenicity, cell cycle distribution, apoptosis, migration, and invasion using MTT, colony formation, flow cytometry, and Transwell-based assays.
Results: ACOT7 was markedly over-expressed at both the mRNA and protein levels in CRC cells compared to normal epithelial cells. Silencing ACOT7 substantially reduced cell proliferation and clonogenic potential. Flow cytometric analysis indicated cell cycle arrest and an increase in the sub-G0/G1 population, indicative of apoptosis in ACOT7-depleted cells. Furthermore, suppression of ACOT7 substantially impaired both cell migration and invasion, suggesting its key role in metastatic progression.
Conclusion: These findings highlight ACOT7 as a critical regulator of the proliferation, survival, and metastatic potential of CRC cells and support its candidacy as a potential therapeutic target for colorectal malignancies.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.